Centogene N.V. (CNTG)

2.8000 -0.0500 (-1.75%) At close: 04:00PM EDT

Centogene N.V.

Am Strande 7
Rostock 18055
Germany
49 381 80113 500
https://www.centogene.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 808

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Andrin Oswald M.D., Ph.D.	Advisor	471.14k	N/A	1972
Ms. Kim Stratton	CEO & Member of Management Board	N/A	N/A	1962
Mr. Jose Miguel Coego Rios	Exec. VP of Fin. & Legal and Interim CFO	N/A	N/A	N/A
Dr. Patrice P. Denefle Ph.D.	Chief Scientific Officer	N/A	N/A	1960
Ms. Nathalie Daste	Chief HR Officer	N/A	N/A	1977
Mr. Florian Vogel Ph.D.	Chief Process Officer	N/A	N/A	1981
Dr. Peter Bauer M.D.	Chief Genomic Officer	N/A	N/A	1970
Dr. Gunter Maximilian Schmid M.D.	Chief Commercial Officer of Diagnostics	N/A	N/A	1967
Mr. Lennart M. Streibel	Director of Corp. Projects	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Corporate governance

Centogene N.V.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.